Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CVS
CVS Health To Boost Access To FDA-approved Nasal Naloxone For Patients Without Insurance
CVS Health Says Overdose-Reversal Drug Is Now Available Without A Prescription In Texas
Tesla, Shale, Big Media, Jobs Reports Lead Investing Action Plan (Investor's Business Daily)
Related RM
Benzinga's Top Upgrades
Benzinga's Volume Movers

Analysts at Cantor Fitzgerald downgraded CVS (NYSE: CVS) from “buy” to “hold.” The target price for CVS has been lowered from $65 to $62. CVS's shares closed at $59.89 yesterday.

Jefferies downgraded Regional Management (NYSE: RM) from “buy” to “hold.” The target price for Regional Management is set to $29. Regional Management's shares closed at $31.20 yesterday.

Bank of America downgraded Marathon Oil (NYSE: MRO) from “buy” to “neutral.” The target price for Marathon Oil has been lowered from $45 to $42. Marathon Oil's shares closed at $36.88 yesterday.

Analysts at McNicoll Lewis Vlak downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) from “buy” to “hold.” The target price for ACADIA Pharmaceuticals has been raised from $18 to $20. ACADIA's shares closed at $20.68 yesterday.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2016Morgan StanleyDowngradesEqual-weight
May 2016JefferiesMaintainsBuy
May 2016CitigroupMaintainsNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ACAD + CVS)

View Comments and Join the Discussion!